Cargando…
Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project
Aim: Advanced glycation end-products (AGEs) have been involved in the atherogenic process in the high-risk population. The goal of this study was to demonstrate that AGEs are related to subclinical atheromatous disease in subjects with low to moderate vascular risk. Methods: A cross-sectional study...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Atherosclerosis Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800392/ https://www.ncbi.nlm.nih.gov/pubmed/30842389 http://dx.doi.org/10.5551/jat.47498 |
_version_ | 1783460432250404864 |
---|---|
author | Sánchez, Enric Betriu, Àngels Yeramian, Andree Fernández, Elvira Purroy, Francesc Sánchez-de-la-Torre, Manuel Pamplona, Reinald Miquel, Eva Kerkeni, Mohsen Hernández, Cristina Simó, Rafael Lecube, Albert Hernández, Marta Rius, Ferran Polanco, Dinora Barbé, Ferran Torres, Gerard Suárez, Guillermo Portero-Otin, Manuel Jové, Mariona Colàs-Campàs, Laura Benabdelhak, Ikram Farràs, Cristina Ortega, Marta Valdivielso, José Manuel Bermúdez-López, Marcelino Martínez-Alonso, Montse |
author_facet | Sánchez, Enric Betriu, Àngels Yeramian, Andree Fernández, Elvira Purroy, Francesc Sánchez-de-la-Torre, Manuel Pamplona, Reinald Miquel, Eva Kerkeni, Mohsen Hernández, Cristina Simó, Rafael Lecube, Albert Hernández, Marta Rius, Ferran Polanco, Dinora Barbé, Ferran Torres, Gerard Suárez, Guillermo Portero-Otin, Manuel Jové, Mariona Colàs-Campàs, Laura Benabdelhak, Ikram Farràs, Cristina Ortega, Marta Valdivielso, José Manuel Bermúdez-López, Marcelino Martínez-Alonso, Montse |
author_sort | Sánchez, Enric |
collection | PubMed |
description | Aim: Advanced glycation end-products (AGEs) have been involved in the atherogenic process in the high-risk population. The goal of this study was to demonstrate that AGEs are related to subclinical atheromatous disease in subjects with low to moderate vascular risk. Methods: A cross-sectional study in which 2,568 non-diabetic subjects of both sexes without cardiovascular disease were included. Subcutaneous content of AGEs was assessed by skin autofluorescence (SAF) and subclinical atheromatous disease was measured by assessing the atheromatous plaque burden in carotid and femoral regions using ultrasonography. In addition, serum pentosidine, carboxymethyl-lysine (CML) and AGE receptors (RAGE) were assessed in a nested case-control study with 41 subjects without plaque and 41 individuals subjects with generalized disease. Results: Patients with atheromatous plaque had a higher SAF than those with no plaque (1.9 [1.7 to 2.3] vs. 1.8 [1.6 to 2.1] arbitrary units (AU), p % 0.001). The SAF correlated with the total number of affected regions (r = 0.171, p < 0.001), increasing progressively from 1.8 [1.6 to 2.1] AU in those without atheromatous disease to 2.3 [1.9 to 2.7] AU in patients with ≥ 8 plaques (p < 0.001). A correlation was also observed between SAF and the total plaque area (r = 0.113, p < 0.001). The area under the Receiver Operating Characteristic curve was 0.65 (0.61 to 0.68) for identifying male subjects with atheromatous disease. The multivariable logistic regression model showed a significant and independent association between SAF and the presence of atheromatous disease. However, no significant differences in serum pentosidine, CML, and RAGE were observed. Conclusions: Increased subcutaneous content of AGEs is associated with augmented atheromatous plaque burden. Our results suggest that SAF may provide clinically relevant information to the current strategies for the evaluation of cardiovascular risk, especially among the male population. |
format | Online Article Text |
id | pubmed-6800392 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Japan Atherosclerosis Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-68003922019-10-25 Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project Sánchez, Enric Betriu, Àngels Yeramian, Andree Fernández, Elvira Purroy, Francesc Sánchez-de-la-Torre, Manuel Pamplona, Reinald Miquel, Eva Kerkeni, Mohsen Hernández, Cristina Simó, Rafael Lecube, Albert Hernández, Marta Rius, Ferran Polanco, Dinora Barbé, Ferran Torres, Gerard Suárez, Guillermo Portero-Otin, Manuel Jové, Mariona Colàs-Campàs, Laura Benabdelhak, Ikram Farràs, Cristina Ortega, Marta Valdivielso, José Manuel Bermúdez-López, Marcelino Martínez-Alonso, Montse J Atheroscler Thromb Original Article Aim: Advanced glycation end-products (AGEs) have been involved in the atherogenic process in the high-risk population. The goal of this study was to demonstrate that AGEs are related to subclinical atheromatous disease in subjects with low to moderate vascular risk. Methods: A cross-sectional study in which 2,568 non-diabetic subjects of both sexes without cardiovascular disease were included. Subcutaneous content of AGEs was assessed by skin autofluorescence (SAF) and subclinical atheromatous disease was measured by assessing the atheromatous plaque burden in carotid and femoral regions using ultrasonography. In addition, serum pentosidine, carboxymethyl-lysine (CML) and AGE receptors (RAGE) were assessed in a nested case-control study with 41 subjects without plaque and 41 individuals subjects with generalized disease. Results: Patients with atheromatous plaque had a higher SAF than those with no plaque (1.9 [1.7 to 2.3] vs. 1.8 [1.6 to 2.1] arbitrary units (AU), p % 0.001). The SAF correlated with the total number of affected regions (r = 0.171, p < 0.001), increasing progressively from 1.8 [1.6 to 2.1] AU in those without atheromatous disease to 2.3 [1.9 to 2.7] AU in patients with ≥ 8 plaques (p < 0.001). A correlation was also observed between SAF and the total plaque area (r = 0.113, p < 0.001). The area under the Receiver Operating Characteristic curve was 0.65 (0.61 to 0.68) for identifying male subjects with atheromatous disease. The multivariable logistic regression model showed a significant and independent association between SAF and the presence of atheromatous disease. However, no significant differences in serum pentosidine, CML, and RAGE were observed. Conclusions: Increased subcutaneous content of AGEs is associated with augmented atheromatous plaque burden. Our results suggest that SAF may provide clinically relevant information to the current strategies for the evaluation of cardiovascular risk, especially among the male population. Japan Atherosclerosis Society 2019-10-01 /pmc/articles/PMC6800392/ /pubmed/30842389 http://dx.doi.org/10.5551/jat.47498 Text en 2019 Japan Atherosclerosis Society This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Original Article Sánchez, Enric Betriu, Àngels Yeramian, Andree Fernández, Elvira Purroy, Francesc Sánchez-de-la-Torre, Manuel Pamplona, Reinald Miquel, Eva Kerkeni, Mohsen Hernández, Cristina Simó, Rafael Lecube, Albert Hernández, Marta Rius, Ferran Polanco, Dinora Barbé, Ferran Torres, Gerard Suárez, Guillermo Portero-Otin, Manuel Jové, Mariona Colàs-Campàs, Laura Benabdelhak, Ikram Farràs, Cristina Ortega, Marta Valdivielso, José Manuel Bermúdez-López, Marcelino Martínez-Alonso, Montse Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project |
title | Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project |
title_full | Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project |
title_fullStr | Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project |
title_full_unstemmed | Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project |
title_short | Skin Autofluorescence Measurement in Subclinical Atheromatous Disease: Results from the ILERVAS Project |
title_sort | skin autofluorescence measurement in subclinical atheromatous disease: results from the ilervas project |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800392/ https://www.ncbi.nlm.nih.gov/pubmed/30842389 http://dx.doi.org/10.5551/jat.47498 |
work_keys_str_mv | AT sanchezenric skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT betriuangels skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT yeramianandree skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT fernandezelvira skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT purroyfrancesc skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT sanchezdelatorremanuel skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT pamplonareinald skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT miqueleva skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT kerkenimohsen skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT hernandezcristina skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT simorafael skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT lecubealbert skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT hernandezmarta skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT riusferran skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT polancodinora skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT barbeferran skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT torresgerard skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT suarezguillermo skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT porterootinmanuel skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT jovemariona skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT colascampaslaura skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT benabdelhakikram skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT farrascristina skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT ortegamarta skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT valdivielsojosemanuel skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT bermudezlopezmarcelino skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject AT martinezalonsomontse skinautofluorescencemeasurementinsubclinicalatheromatousdiseaseresultsfromtheilervasproject |